Accretion Nutraveda
Close ·
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · TTM
- ROCE
- 27.70%
- Debt to Equity
- 0.12
- EPS (TTM)
- —
- Book Value
- ₹49.00
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 6.35
- ROE
- 25.00%
- Dividend Yield
- 0.00%
- EBITDA
- ₹7.00 Cr
- 52W High
- ₹348.00
- 52W Low
- ₹150.10
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 111 days to 196 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 0 | 9 | 10 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 0 | 2 | 8 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 57.43
- Neutral
- MACD (12,26,9)
- 7.11
- Bullish
- SMA (50)
- 287.62
- Bullish
- SMA (200)
- —
- Neutral
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +126.52% |
|---|---|
| 1Y | +109.94% |
Net profit
| 3Y | +162.59% |
|---|---|
| 1Y | +102.80% |
Operating cash flow
| 3Y | Turned negative |
|---|---|
| 1Y | Outflow widened by ₹7.20 Cr |
Operating margin· change in pp
| 3Y | −0.94 pp |
|---|---|
| 1Y | −2.68 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2023 | ₹2.89 Cr |
|---|---|
| Mar 2024 | ₹5.01 Cr |
| Mar 2025 | ₹16.00 Cr |
| Mar 2026 | ₹33.59 Cr |
Net profit by year
| Mar 2023 | ₹0.28 Cr |
|---|---|
| Mar 2024 | ₹0.82 Cr |
| Mar 2025 | ₹2.50 Cr |
| Mar 2026 | ₹5.07 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 10.85 | 14.06 | 19.54 |
| Expenses | 8.27 | 10.76 | 15.98 |
| Operating Profit | 2.58 | 3.3 | 3.56 |
| OPM % | 23.78% | 23.47% | 18.22% |
| Other Income | 0 | 0 | 0.11 |
| Interest | 0.26 | 0.26 | 0.27 |
| Depreciation | 0.11 | 0.17 | 0.1 |
| PBT | 2.21 | 2.87 | 3.3 |
| Tax % | 22.17% | 18.47% | 18.48% |
| Net Profit | 1.72 | 2.33 | 2.69 |
| EPS (₹) | 3.51 | 4.38 | 3.72 |
Profit & Loss
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 2.89 | 5.01 | 16 | 33.59 |
| Expenses | 2.27 | 3.78 | 12.29 | 26.7 |
| Operating Profit | 0.62 | 1.23 | 3.71 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% |
| Other Income | 0.17 | 0.19 | 0.01 | 0.11 |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.26 |
| PBT | 0.29 | 0.92 | 3.15 | 6.21 |
| Tax % | 3.45% | 9.78% | 20.63% | 18.36% |
| Net Profit | 0.28 | 0.82 | 2.5 | 5.07 |
| EPS (₹) | 0.78 | 2.28 | 5.1 | 7 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | −0.1 | 0.72 | 4.56 | 28.23 |
| Borrowings | 1.97 | 2.17 | 3.86 | 4.23 |
| Other Liabilities | 1.83 | 1.39 | 1.63 | 2.08 |
| Total Liabilities | 4.06 | 4.64 | 10.54 | 41.78 |
| Fixed Assets | 1.49 | 1.28 | 1.83 | 1.66 |
| CWIP | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 2.57 | 3.26 | 8.71 | 40.12 |
| Total Assets | 4.06 | 4.64 | 10.54 | 41.78 |
Cash Flow
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 0.68 | 0.23 | −2.22 | −9.42 |
| Investing | −0.01 | −0.16 | −0.87 | −14.5 |
| Financing | −0.63 | −0.04 | 2.98 | 25.19 |
| Net Cash Flow | 0.04 | 0.03 | −0.1 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | −3.09 | −15.45 |
| CFO/EBITDA | 110 | 27 | −42 | −113 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 101 | 18.21 | 74.6 | 88.13 |
| Inventory Days | 279 | 304 | 159 | 136 |
| Days Payable | 354 | 114 | 30.73 | 11.35 |
| Cash Conversion Cycle | 25.89 | 208 | 202 | 213 |
| Working Capital Days | 8.84 | 7.29 | 129 | 196 |
| ROCE % | — | 42.34% | 57.57% | 27.73% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Accretion Nutraveda insights
53 extracted metrics across FY23–FY26.
Documents
- General announcements 3 Nov 2026
- General announcements 31 Oct 2026
Frequently Asked Questions about Accretion Nutraveda
What does Accretion Nutraveda Ltd do?
Where is Accretion Nutraveda Ltd (ANL) listed?
Which sector does Accretion Nutraveda Ltd belong to?
What is the 52-week high and low of Accretion Nutraveda Ltd?
What is the Return on Equity (ROE) of Accretion Nutraveda Ltd?
Company Information
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544694.md for Accretion Nutraveda Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.